Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alessandro Granito

Showing results (111-120 of 136) with videos related to

Pageof 14
Sort By:
Liver International : Official Journal of the International Association for the Study of the Liver|March 1, 2013
Patterns of appearance and risk of misdiagnosis of intrahepatic cholangiocarcinoma in cirrhosis at contrast enhanced ultrasoundMarzia Galassi, Massimo Iavarone, Sandro Rossi, et al.
Internal and Emergency Medicine|March 29, 2024
Prediction of cardiovascular risk in patients with hepatocellular carcinoma receiving anti-angiogenic drugs: lessons from sorafenibBernardo Stefanini, Francesco Tovoli, Franco Trevisani, et al.
Transplantation|August 22, 2022
Outcomes of Sorafenib for Recurrent Hepatocellular Carcinoma After Liver Transplantation in the Era of Combined and Sequential TreatmentsFrancesco Tovoli, Dante Pio Pallotta, Vito Sansone, et al.
Journal of Cancer Research and Clinical Oncology|December 18, 2017
Metronomic capecitabine as second-line treatment for hepatocellular carcinoma after sorafenib discontinuationFranco Trevisani, Giovanni Brandi, Francesca Garuti, et al.
Journal of Hepatology|April 29, 2018
Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: Additional analyses from the phase III RESORCE trialRichard S Finn, Philippe Merle, Alessandro Granito, et al.
World Journal of Hepatology|September 26, 2022
Polymorphism AGT2 (rs4762) is involved in the development of dermatologic events: Proof-of-concept in hepatocellular carcinoma patients treated with sorafenibVíctor Sapena, Massimo Iavarone, Loreto Boix, et al.
Targeted Oncology|September 7, 2021
Identification of Regorafenib Prognostic Index (REP Index) via Recursive Partitioning Analysis in Patients with Advanced Hepatocellular Carcinoma Receiving Systemic Treatment: A Real-World Multi-Institutional ExperienceMargherita Rimini, Changhoon Yoo, Sara Lonardi, et al.
Clinical and Translational Science|September 29, 2020
COVID-19 and Immunological Dysregulation: Can Autoantibodies be Useful?Simona Pascolini, Antonio Vannini, Gaia Deleonardi, et al.
Liver Cancer|May 27, 2026
An International Phase 4 Study of Lenvatinib and Sorafenib in Real-World Patients with Unresectable Hepatocellular Carcinoma: Final AnalysisMarkus Peck-Radosavljevic, Akhmed Abdelgafur, Alessandro Granito, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|August 21, 2024
Suboptimal outcomes of sorafenib as a second-line treatment after atezolizumab-bevacizumab for unresectable hepatocellular carcinomaFrancesco Tovoli, Dante Pio Pallotta, Caterina Vivaldi, et al.
Pageof 14

Showing results (111-120 of 136) with videos related to

Sort By:
Pageof 14
Liver International : Official Journal of the International Association for the Study of the Liver|March 1, 2013
Patterns of appearance and risk of misdiagnosis of intrahepatic cholangiocarcinoma in cirrhosis at contrast enhanced ultrasoundMarzia Galassi, Massimo Iavarone, Sandro Rossi, et al.
Internal and Emergency Medicine|March 29, 2024
Prediction of cardiovascular risk in patients with hepatocellular carcinoma receiving anti-angiogenic drugs: lessons from sorafenibBernardo Stefanini, Francesco Tovoli, Franco Trevisani, et al.
Transplantation|August 22, 2022
Outcomes of Sorafenib for Recurrent Hepatocellular Carcinoma After Liver Transplantation in the Era of Combined and Sequential TreatmentsFrancesco Tovoli, Dante Pio Pallotta, Vito Sansone, et al.
Journal of Cancer Research and Clinical Oncology|December 18, 2017
Metronomic capecitabine as second-line treatment for hepatocellular carcinoma after sorafenib discontinuationFranco Trevisani, Giovanni Brandi, Francesca Garuti, et al.
Journal of Hepatology|April 29, 2018
Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: Additional analyses from the phase III RESORCE trialRichard S Finn, Philippe Merle, Alessandro Granito, et al.
World Journal of Hepatology|September 26, 2022
Polymorphism AGT2 (rs4762) is involved in the development of dermatologic events: Proof-of-concept in hepatocellular carcinoma patients treated with sorafenibVíctor Sapena, Massimo Iavarone, Loreto Boix, et al.
Targeted Oncology|September 7, 2021
Identification of Regorafenib Prognostic Index (REP Index) via Recursive Partitioning Analysis in Patients with Advanced Hepatocellular Carcinoma Receiving Systemic Treatment: A Real-World Multi-Institutional ExperienceMargherita Rimini, Changhoon Yoo, Sara Lonardi, et al.
Clinical and Translational Science|September 29, 2020
COVID-19 and Immunological Dysregulation: Can Autoantibodies be Useful?Simona Pascolini, Antonio Vannini, Gaia Deleonardi, et al.
Liver Cancer|May 27, 2026
An International Phase 4 Study of Lenvatinib and Sorafenib in Real-World Patients with Unresectable Hepatocellular Carcinoma: Final AnalysisMarkus Peck-Radosavljevic, Akhmed Abdelgafur, Alessandro Granito, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|August 21, 2024
Suboptimal outcomes of sorafenib as a second-line treatment after atezolizumab-bevacizumab for unresectable hepatocellular carcinomaFrancesco Tovoli, Dante Pio Pallotta, Caterina Vivaldi, et al.
Pageof 14